Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Harries

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Scientific Reports|July 15, 2016
IgG subclass switching and clonal expansion in cutaneous melanoma and normal skinLouise Saul, Kristina M Ilieva, Heather J Bax, et al.
The Journal of Clinical Investigation|March 5, 2013
IgG4 subclass antibodies impair antitumor immunity in melanomaPanagiotis Karagiannis, Amy E Gilbert, Debra H Josephs, et al.
JAMA Oncology|February 16, 2023
Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced MelanomaLaura A Bolte, Karla A Lee, Johannes R Björk, et al.
Melanoma Research|July 31, 2015
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patientsSaif S Ahmad, Wendi Qian, Sarah Ellis, et al.
Ebiomedicine|August 25, 2022
Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanomaNiccolò Rossi, Karla A Lee, Maria V Bermudez, et al.
BMC Cancer|February 22, 2023
Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanomaAlessia Visconti, Niccolò Rossi, Helena Deriš, et al.
Lancet (London, England)|June 11, 2019
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trialHelena M Earl, Louise Hiller, Anne-Laure Vallier, et al.
Nature Medicine|May 2, 2018
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialAndrew Tutt, Holly Tovey, Maggie Chon U Cheang, et al.
Nature Medicine|March 1, 2022
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanomaKarla A Lee, Andrew Maltez Thomas, Laura A Bolte, et al.
Nature Medicine|February 16, 2024
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanomaJohannes R Björk, Laura A Bolte, Andrew Maltez Thomas, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Scientific Reports|July 15, 2016
IgG subclass switching and clonal expansion in cutaneous melanoma and normal skinLouise Saul, Kristina M Ilieva, Heather J Bax, et al.
The Journal of Clinical Investigation|March 5, 2013
IgG4 subclass antibodies impair antitumor immunity in melanomaPanagiotis Karagiannis, Amy E Gilbert, Debra H Josephs, et al.
JAMA Oncology|February 16, 2023
Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced MelanomaLaura A Bolte, Karla A Lee, Johannes R Björk, et al.
Melanoma Research|July 31, 2015
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patientsSaif S Ahmad, Wendi Qian, Sarah Ellis, et al.
Ebiomedicine|August 25, 2022
Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanomaNiccolò Rossi, Karla A Lee, Maria V Bermudez, et al.
BMC Cancer|February 22, 2023
Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanomaAlessia Visconti, Niccolò Rossi, Helena Deriš, et al.
Lancet (London, England)|June 11, 2019
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trialHelena M Earl, Louise Hiller, Anne-Laure Vallier, et al.
Nature Medicine|May 2, 2018
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialAndrew Tutt, Holly Tovey, Maggie Chon U Cheang, et al.
Nature Medicine|March 1, 2022
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanomaKarla A Lee, Andrew Maltez Thomas, Laura A Bolte, et al.
Nature Medicine|February 16, 2024
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanomaJohannes R Björk, Laura A Bolte, Andrew Maltez Thomas, et al.
Pageof 6